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Abstract
Prevalence of sexually transmitted infections (STI) is high among pregnant women in certain
settings. We estimated STI incidence and compared STI risk in pregnant and non-pregnant
women. Data came from the Methods for Improving Reproductive Health in Africa (MIRA)
study conducted in South Africa and Zimbabwe 2003–2006. Women aged 18–50 years with
at least one follow-up visit within 6 months of enrollment were included. Follow-up visits
included laboratory testing for pregnancy, chlamydia, gonorrhea, trichomoniasis, and HIV, as
well as self-report of hormonal contraceptive (HC) use, sexual behaviors and intravaginal
practices. All visits were classified according to pregnancy status. Incidence of each STI was
calculated using follow-up time. Cox proportional hazards models were fitted using pregnancy
as a time-varying exposure and sexual behaviors and intravaginal practices as time-varying
covariates. Among 4,549 women, 766 (16.8%) had a positive pregnancy test. Median follow-
up time was 18 months [IQR: 12–24]. The overall incidence rate of chlamydia was 6.7 per 100
person years (py) and 9.9/100py during pregnancy; gonorrhea incidence was 2.7/100py and
4.9/100py during pregnancy; trichomoniasis incidence was 7.1/100py overall and 9.2/100py
during pregnancy. Overall HIV incidence was 3.9/100py and 3.8/100py during pregnancy. In
crude models, pregnancy increased risk for chlamydia (hazard ratio (HR) 1.5, 95%CI:
1.1–1.2), however there was no increased risk of any measured STI in adjusted models. STI
Incidence was high during pregnancy however pregnancy did not increase STI risk after
adjustment for sexual behaviors. Greater efforts are needed to help pregnant women avoid
STIs.
Introduction
High prevalence of sexually transmitted infections (STI) has been observed in some popula-
tions of pregnant women. Data from routine screening in antenatal care settings in sub-Saha-
ran Africa have shown prevalence of common STIs, including chlamydia, gonorrhea and
syphilis, to be as high as 15% [1, 2].. Almost half of all women under 30 years of age are infected







Citation: Teasdale CA, Abrams EJ, Chiasson MA,
Justman J, Blanchard K, Jones HE (2018)
Incidence of sexually transmitted infections during
pregnancy. PLoS ONE 13(5): e0197696. https://
doi.org/10.1371/journal.pone.0197696
Editor: Matthew Chico, London School of Hygiene
and Tropical Medicine Department of Population
Health, UNITED KINGDOM
Received: September 18, 2017
Accepted: May 7, 2018
Published: May 24, 2018
Copyright: © 2018 Teasdale et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The data underlying
this study are from the Methods for Improved
Reproductive Health in Africa (MIRA) study
(ClinicalTrials.gov: NCT00121459). Data accession
requests may be sent to Dr. Elizabeth Montgomery
at RTI International (emontgomery@rti.org). The
authors did not have special access privileges.
Funding: The analysis presented here is a
secondary analysis that did not receive funding.
Details regarding funding for the MIRA trial have
been previously published (Padian NS et al.
with Herpes Simplex Virus type 2 (HSV-2] across sub-Saharan Africa [3] and up to 30% of
pregnant women have HIV in southern Africa [4]. Pregnant adolescents in other parts of the
world have also been found to have high STI prevalence; in Portugal one study found 11% of
pregnant teenagers to be infected with trichomoniasis and 5% with gonorrhea [5].
STIs can cause chronic pain as well as permanent infertility in women who do not receive
treatment and are of particular concern during pregnancy as they are associated with adverse
outcomes including stillbirth and low birth weight and some can also be transmitted to infants
leading to blindness and developmental delays [6, 7]. HIV is the leading cause of maternal
mortality in high prevalence settings, increasing the risk of death six-fold for pregnant women
and new mothers [8]. Mother-to-child transmission (MTCT) of HIV and HSV-2 results in life-
long infection and HIV is associated with high mortality in untreated infected children [9, 10].
Incident maternal infection with HIV and HSV-2 during pregnancy may confer higher risk of
MTCT [10, 11].
While a small number of studies have shown that incidence of common curable STIs, as
well as HIV, continues during pregnancy, few have evaluated whether pregnancy increases the
risk of STI acquisition [12–16]. Studies have compared incidence in pregnant and non-preg-
nant women only for HPV and HIV showing no increased risk of HPV during pregnancy [13]
but conflicting results for HIV [17–19]. Data indicate that pregnant women tend to report less
condom use compared to women who are not pregnant which could increase STI incidence
[20, 21]. In addition to sexual risk behaviors, intravaginal practices, including douching, clean-
ing, wiping and insertion of materials and substances into the vagina, have also been studied as
potential risk factors for STI acquisition, particularly HIV [22], and may vary during preg-
nancy [21]. Alternations in immune function [23–25] and physiological changes to the cervix
that occur during pregnancy are thought to be potential biological pathways of increased risk
[26–29].
In light of the significant consequences of STIs for women and their children, it is critical to
investigate whether pregnancy increases a woman’s risk of STI acquisition. In this analysis, we
measured incidence of four common STIs (chlamydia, gonorrhea, trichomoniasis and HIV)
among pregnant and non-pregnant women and compared STI risk based on pregnancy status
using data from a randomized clinical trial conducted in South Africa and Zimbabwe.
Methods
Data came from the Methods for Improved Reproductive Health in Africa (MIRA) study, an
open-label trial of the diaphragm and lubricant gel for prevention of HIV infection in women
which was approved by institutional review boards (IRB) in the United States, South Africa
and Zimbabwe (ClinicalTrials.gov: NCT00121459). The MIRA trial enrolled HIV-negative
women >18 years of age in South Africa and Zimbabwe. During 12–24 months of study fol-
low-up, participants attended quarterly visits which included STI/HIV testing, and risk reduc-
tion counseling including unlimited condoms. Participants self-reported sexual activity,
contraceptive and condom use, and intravaginal practices through clinician-administered
interviews and audio computer-assisted self-interviewing (ACASI). Women who became
pregnant continued in the study during and after pregnancy (women in the diaphragm arm
had the option to discontinue use). All women testing positive for HIV were referred for treat-
ment; treatment for curable STIs was given at study sites. Data were not available from care
women may have received at non-study health facilities.
For this analysis, we included HIV-negative women 18–50 years of age, including those
who tested positive and received treatment for chlamydia, gonorrhea, trichomoniasis and
syphilis at enrollment. Women were excluded from the analysis if their first study visit was
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more than six months after the enrollment date and if they tested positive for chlamydia, gon-
orrhea or trichomoniasis at the two week visit (indicating incomplete treatment or treatment
failure at enrollment). Data from study visits that occurred more than six weeks after a woman
gave birth were excluded as incidence of STIs during the post-partum period may differ from
other non-pregnant periods [30]. In addition, visits with greater than a six month gap were
censored at the last visit prior to the gap, as were visits that occurred after an HIV diagnosis as
behavior may change following diagnosis.
Pregnancy status was ascertained through urine testing at all scheduled visits (pregnancy
testing was not conducted when women attended non-quarterly visits to receive care for STI
symptoms). Women were considered pregnant if they had a positive human chorionic gonad-
otropin (HCG) urine pregnancy test and non-pregnant at all visits with negative pregnancy
tests even if they reported pregnancies between visits resulting in miscarriage or termination.
Pregnancy status at a given visit determined exposure status during the interval of time prior
to that visit (if a woman was pregnant at her third quarterly visit, she was considered pregnant
for the full interval between the second and third visits). Women did not report last menstrual
period and ultrasound testing was not used to determine gestational age; women were consid-
ered to be pregnant for the entire interval for the visit when they became pregnant. Visits
within six weeks of a birth were considered pregnant because women were pregnant for most
of the visit interval. Given the potential for hormonal contraceptives (HC) to increase risk of
STI/HIV [31, 32], non-pregnant visits were further classified into three groups according to
self-reported HC use: oral contraceptives (combined estrogen and progesterone and progester-
one-only pills), injectable HC (Net-En and Depo Provera), and no use of HC including report
of condoms, diaphragm and natural methods or no method. For women with two pregnancies
during follow-up, only the first pregnancy was included in the analysis.
Four STI outcomes were examined: chlamydia, gonorrhea, trichomoniasis and HIV. DNA
polymerase chain reaction (PCR) testing of urine was used to diagnosis chlamydia, gonorrhea
and trichomoniasis (Roche COBAS1 AMPLICOR, Branchburg, NJ, USA). Two rapid HIV
tests were conducted on whole blood samples with Determine HIV-1/2 (Abbot Laboratories,
Tokyo, Japan) or Oraquick (Orasure Technologies, Bethlehem, PA, USA). Discordant rapid
tests were confirmed with enzyme-linked immunosorbent assay (ELISA). Testing laboratories
in Zimbabwe and South Africa were monitored for quality control during the study. As previ-
ous data have shown that PCR testing of urine may have lower sensitivity and specificity for
detecting chlamydia, gonorrhea and trichomoniasis (compared to vaginal swabs), we report
both the observed and adjusted prevalence estimates [33] at enrollment for the three infections
using estimated sensitivity and specificity estimates for urine testing [34, 35].
We estimated time to first incident infection of each of the four STIs (incident infection
defined as the first positive test after a previous negative test). STI infection outcomes were
assigned to the quarterly study visit with positive test result and matched with the behavioral
data reported at the same visit corresponding to the period prior to the visit. Positive STI test
results from non-quarterly visits (when women sought additional services generally due to
symptoms) were carried forward to the subsequent quarterly study visit and matched with the
corresponding behavior data from the same visit interval.
Hypothesized confounders included age, education, intervention arm (diaphragm or con-
trol) and contraceptive use at enrollment, along with a variable indicating any report at enroll-
ment of high risk sexual behaviors including anal sex, sex in exchange for drugs or money, two
or more sexual partners, new sexual partner or sex under the influence of drugs or alcohol.
Women also reported male partners risk behaviors at enrollment with data summarized into a
high risk variable indicating any HIV-infected status, away from home>one month in past
year, use of drugs during sex or suspicion or knowledge of other sex partners. Behaviors
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reported by women at all quarterly study visits included frequency of sexual activity, condom
use, sex in exchange for money or drugs, two or more sex partners, new sex partner and sus-
pecting or knowing that a male partner had other partners. Intravaginal practices were catego-
rized into three groups: washing, wiping, or inserting paper products into the vagina (not for
menstruation).
Descriptive statistics were used to compare demographic characteristics and frequency of
reported sexual behaviors and intravaginal practices at enrollment for women with and with-
out positive pregnancy tests. To estimate incidence of STIs during pregnant and non-pregnant
periods, each of the four STIs was examined separately with follow-up time for participants
calculated from enrollment date to the first diagnosis of each STI or end of follow-up. For
intervals between visits culminating in incident STI infection, the midpoint between visits
with the last negative and first positive test was used. Follow-up time at risk was estimated by
summing the intervals of time between visits for each participant based on four exposure
groups assigned to each visit interval: pregnant, non-pregnant/oral HC, non-pregnant/
injectable HC and non-pregnant/no HC use. Incidence rates in person years were calculated
by dividing the corresponding follow-up time at risk for each exposure group separately as
well as overall.
Bivariable and multivariable Cox proportional hazards models were fitted to examine preg-
nancy status and incidence of the four STI separately and a composite endpoint of first inci-
dence of any of four infections. Adjusted models included a priori hypothesized confounders.
Pregnancy was treated as a time-varying exposure and sexual risk behaviors and vaginal prac-
tices were treated as time-varying confounders; demographic and enrollment characteristics
were modeled as time-fixed confounders. Study location was tested for effect measure modifi-
cation using a cross-product term of location and pregnancy status.
Results
Of the 4,948 women analyzed in the MIRA trial, 4,935 (99.7%) were 18–50 years of age at
enrollment and among those, 4,553 (92.3%) had at least one follow-up visit with STI and preg-
nancy testing within six months of the date of enrollment (four women were excluded as a
result of incomplete treatment for curable STIs at enrollment). Among 4,549 women included
in the analysis, 766 (16.8%) had a positive pregnancy test during follow-up (35 women
reported a termination, 83 women reported miscarriages and one woman reported an ectopic
pregnancy). Of the 24,337 visits included in the analysis, 1,609 (6.6%) occurred during a preg-
nancy. Median follow-up time was 15 months [IQR: 12–21] for women with pregnancies and
18 months [IQR: 12–24] for women without a pregnancy (p = 0.47).
At enrollment, women who became pregnant during follow-up were more likely to be from
Zimbabwe and were younger; median age for women with pregnancies was 25 years (inter-
quartile range (IQR): 21–30) whereas median age of women without pregnancies was 28 years
(IQR: 23–35) (p<0.0001) (Table 1). Compared to women who did not have pregnancies,
women with pregnancies were more likely to have completed high school and were less like to
have children at enrollment; they were also more likely to report use of oral contraceptives, to
have had two or more sexual partners at enrollment and to be infected with HSV-2 (Table 1).
There were no other differences in demographics or reported sexual behaviors, male partner
characteristics or STI status.
Overall incidence of chlamydia was 6.7 per 100 person years (py) and was highest when
women were using injectable HC (10.1/100py) (Table 2). Gonorrhea and trichomoniasis inci-
dence overall were 2.7/100py and 7.1/100py, respectively, and both were highest during peri-
ods when women were pregnant; 4.9/100py and 9.2/100py. The rate of HIV incidence overall
Incidence of sexually transmitted infections during pregnancy
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Table 1. Characteristics at enrollment of 4,549 MIRA participants with and without pregnancies during follow-up.
Characteristics at enrollment Total Women with no pregnancies Women with lab confirmed
pregnancies
N % N % N %
4549 100.0% 3783 83.2% 766 16.8%
Study location
Harare 2255 49.6% 1847 48.9% 408a 53.3%
Durban 1372 30.2% 1173 30.9% 199 26.0%
Johannesburg 922 20.3% 763 20.2% 159 20.8%
Age
Median age (IQR) 27 (22–34) 28 (23–35) 25b (21–30)
18–24 1725 37.9% 1342 35.5% 383 50.0%
25–34 1782 39.2% 1472 38.9% 310 40.5%
35 1042 22.9% 969 25.6% 73 9.5%
Completed high school (11 yrs school) 2347 51.6% 1904 50.3% 443c 57.8%
Paid employment 1039 22.4% 883 23.4% 156 20.4%
Married 2695 59.3% 2245 59.4% 450 58.8%
Lives with male partner 3081 67.7% 2572 68.0% 509 66.5%
Number or previous pregnancies
None 387 8.5% 280 7.4% 107b 14.0%
1 previous pregnancy 1446 31.8% 1151 30.4% 295 38.5%
2+ previous pregnancies 2716 59.7% 2352 62.2% 364 47.5%
Current birth control (not mutually exclusive)
Combined pills 991 21.8% 770 20.4% 221b 28.9%
Injectable hormones 1129 24.8% 1029 27.2% 100b 13.1%
Progesterone only pills 663 14.6% 566 15.0% 97 12.7%
Intrauterine device 16 0.4% 15 0.4% 1 0.1%
Condoms (male or female) (only) 1723 37.9% 1419 37.5% 304 39.7%
None (natural, withdrawal, tradition) 247 5.4% 194 5.1% 53 6.9%
Regular sexual partner 1852 40.7% 1537 40.6% 315 41.1%
Age at first sex, mean (IQR) 18 (16–19) 18 (16–19) 18 (16–19)
Sex acts per week
None 1877 41.3% 1551 41.0% 326 42.6%
1–2 per week 275 6.1% 227 6.0% 48 6.3%
3 per week 2397 52.7% 2005 53.0% 392 51.2%
Number of sexual partners in past 3 months
None 273 6.0% 249 6.6% 24b 3.1%
1 partner 3877 85.5% 3222 85.4% 655 85.5%
2+ 387 8.5% 300 8.0% 87.0 11.4%
Condom use (male or female) at last sex 3200 70.4% 2653 70.1% 547 71.4%
Condom use (vaginal sex) in last three months
Never 1338 29.5% 1132 30.0% 206 26.9%
Sometimes 1767 38.9% 1449 38.4% 318 41.5%
Every time 1433 31.6% 1191 31.6% 242 31.6%
Exchange for money or drugs past 3 months 360 7.9% 303 8.0% 57 7.4%
Anal sex (ever) 669 14.8% 53 14.7% 116 15.1%
Sex while intoxicated 168 26.7% 136 26.8% 32 26.0%
High risk 1059 23.3% 874 23.1% 185 24.2%
(>2 partners, exchange, anal, sex w/ drugs/alcohol)
(Continued)
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was 3.9/100py with highest incidence occurring when women reported injectable HC (4.8/
100py) (Table 2).
In unadjusted models, pregnancy was associated with an increased risk of chlamydia com-
pared to non-pregnant periods with no HC use (hazard ratio (HR) 1.5; 95%CI 1.1–2.2)
Table 1. (Continued)
Characteristics at enrollment Total Women with no pregnancies Women with lab confirmed
pregnancies
N % N % N %
Partner age
Same age (+/-5 years) 2510 57.8% 2077 57.7% 433 58.2%
Younger (more than 5 years) 50 1.2% 47 1.3% 3 0.4%
Older (more than 5 years) 1785 41.1% 1477 41.0% 308 41.4%
Partner tested HIV positive
Yes 156 3.4% 135 3.6% 21 2.7%
No/don’t know 4380 96.6% 3635 96.4% 745 97.3%
Partner away from home >2 months 490 10.9% 413 10.9% 77 10.1%
Partner circumcised 976 21.5% 805 21.4% 171 22.3%
Suspects/knows partner concurrency 1392 30.7% 1159 30.7% 233 30.4%
Physical or verbal abuse 821 33.0% 693 33.0% 128 33.4%
Partner used force to get sex 244 9.8% 208 9.9% 36 9.4%
Sex w/ partner with drugs or alcohol 1622 35.9% 1351 36.0% 271 35.5%
Partner high risk 2836 62.3% 2363 62.5% 473 61.8%
(HIV+, away >1 month, other partners, drugs)
Vaginal washing 3756 82.6% 3119 82.5% 637 83.2%
Vaginal wiping 2560 56.3% 2117 56.0% 443 57.8%
Vaginal insertion (non-menstruation related) 946 20.8% 790 20.9% 156 20.4%
Diaphragm arm 2273 50.0% 1890 50.0% 383 50.0%
Positive for STI (enrollment)
Chlamydia 195 4.3% 155 4.1% 40 5.2%
Corrected chlamydia prevalence estimate 4.6% 4.3% 5.7%
Gonorrhea 34 0.8% 29 0.8% 5 0.7%
Corrected chlamydia prevalence estimate 0.9% 0.9% 1.1%
Trichomoniasis 166 3.7% 133 3.5% 33 4.3%
Corrected chlamydia prevalence estimate 3.1% 2.8% 4.0%





Table 2. Incidence rates of four STIs by pregnancy and hormonal contraceptive exposure group.


























Chlamydia 400 5935 6.7 38 383 9.9 84 2066 4.1 146 1440 10.1 132 2045 6.5
Gonorrhea 165 6130 2.7 20 406 4.9 34 2114 1.6 49 1508 3.2 62 2103 2.9
Trichomoniasis 420 5935 7.1 36 390 9.2 115 2040 5.6 109 1469 7.4 160 2036 7.9
HIV 240 6199 3.9 16 417 3.8 56 2127 2.6 74 1530 4.8 94 2124 4.4
https://doi.org/10.1371/journal.pone.0197696.t002
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Table 3. Crude and adjusteda hazard ratios estimating the relationship between pregnancy status and incident STIs (N = 4,549).
Chlamydia Gonorrhea Trichomoniasis
HR 95%CI AHRa 95%CI HR 95%CI AHRa 95%CI HR 95%
CI
AHRa 95%CI
Pregnancy exposure group (ref: not pregnant/noHC)
Pregnant 1.52 1.06–2.18b 1.29 0.89–1.88 1.59 0.96–2.63 1.52 0.89–2.57 1.13 0.79–
1.62
1.27 0.86–1.86
Not pregnant/oral HC 0.65 0.49–0.85c 0.92 0.63–1.33 0.55 0.36–0.84 0.83 0.47–1.47 0.72 0.57–
0.91b
0.92 0.65–1.29
Not pregnant/injectable HC 1.57 1.24–1.98c 1.32 0.99–1.76 1.09 0.75–1.59 0.94 0.60–1.47 0.94 0.74–
1.20
0.99 0.73–1.40
Study location (ref: Harare, Zimbabwe)
Johannesburg, South Africa 2.73 2.15–3.47d 2.33 1.71–3.19d 2.89 2.00–4.16d 2.19 1.34–3.59c 1.74 1.40–
2.15d
1.51 1.14–1.99c




18–24 years 4.95 3.46–7.09d 5.49 3.74–8.06d 4.17 2.46–7.06d 5.31 3.01–9.36d 0.96 0.76–
1.22
1.23 0.94–1.62
25–34 years 2.09 1.43–3.06c 2.41 1.62–3.58d 1.79 1.02–3.15b 2.27 1.26–4.01b 0.73 0.57–
0.93b
0.89 0.68–1.17
Completed high school 1.45 1.19–1.77 1.09 0.88–1.36 1.30 0.96–1.77 0.97 0.70–1.35 0.74 0.61–
0.90c
0.82 0.66–1.01
Diaphragm arm 1.20 0.99–1.46 1.16 0.94–1.44 0.94 0.69–1.28 1.03 0.75–1.43 0.92 0.76–
1.12
0.93 0.75–1.14
Contraceptive use at enrollment (ref: none)
Oral contraceptives 0.65 0.45–0.95b 1.03 0.65–1.63 0.89 0.47–1.70 1.75 0.81–3.76 0.52 0.39–
0.70d
0.81 0.55–1.21
Injectable contraceptives 1.43 1.00–2.05 0.95 0.64–1.42 1.61 0.86–3.03 1.40 0.71–2.78 0.66 0.49–
0.90b
0.74 0.52–1.06
Othere 1.19 0.83–1.71 1.07 0.74–1.54 1.78 0.96–3.31 1.68 0.90–3.13 0.56 0.41–
0.76c
0.60 0.44–0.82c
High risk sex at enrollmentf 1.28 1.03–1.59 1.21 0.97–1.52 0.79 0.53–1.16 0.68 0.46–1.02 1.22 0.98–
1.51
1.12 0.89–1.40
Partner circumcised at enrollment 1.24 0.99–1.56 1.09 0.85–1.39 1.65 1.19–2.31b 1.57 1.01–2.25b 1.00 0.79–
1.27
1.00 0.78–1.29
Partner high risk at enrollment 1.25 1.02–1.54 1.04 0.83–1.29 1.77 1.25–2.51c 1.40 0.97–2.00 1.39 1.13–
1.71c
1.02 0.96–1.48
STI at enrollment g 1.21 0.99–1.49 1.47 1.18–1.82c 1.90 1.34–2.70c 2.16 1.50–3.11d 1.96 1.57–
2.44d
1.80 1.42–2.27d
Vaginal sex since last visit (ref: none) 0.89 0.60–1.35 0.91 0.56–1.48 1.00 0.51–1.96 1.09 0.51–2.34 0.82 0.56–
1.22
0.82 0.51–1.30
3 Vaginal sex acts per week (ref:0–2) 0.94 0.75–1.16 1.18 0.93–1.51 0.70 0.50–0.96b 0.83 0.59–1.19 0.79 0.64–
0.98b
0.91 0.72–1.16
No condom use at last sex 1.06 0.84–1.33 0.93 0.71–1.21 0.61 0.41–0.92b 0.56 0.36–0.89b 1.05 0.84–
1.32
1.04 0.79–1.36
Unprotected sex since last visit 1.41 1.41–1.74c 1.27 0.99–1.63 1.12 0.82–1.54 1.20 0.84–1.71 1.18 0.97–
1.44
1.07 0.84–1.36
Sex in exchange for drugs or money 1.68 1.06–2.66b 1.30 0.80–2.13 1.50 0.70–3.21 1.36 0.61–3.06 1.61 1.02–
2.55b
1.16 0.71–1.88
2 or more sexual partners 2.89 2.22–3.77d 1.55 1.13–2.14c 2.97 1.98–4.47d 1.36 0.83–2.23 2.13 1.60–
2.84d
1.77 1.26–2.49c
New sexual partner 1.85 1.44–2.37d 1.12 0.85–1.49 2.36 1.64–3.39d 1.48 0.98–2.25 1.93 1.22–
2.04c
1.11 0.83–1.48
Suspects/knows partner concurrency 1.65 1.34–2.02d 1.21 0.97–1.52 2.42 1.78–3.30d 1.70 1.21–2.39c 1.50 1.22–
1.84c
1.22 0.98–1.52
Vaginal washing (any reported) 0.98 0.78–1.23 0.96 0.75–1.23 1.09 0.76–1.57 1.13 0.76–1.67 1.01 0.81–
1.27
1.03 0.81–1.31
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(Table 3). In multivariable adjusted models however, the effect of pregnancy on chlamydia
incidence was attenuated and no longer significant. Pregnancy also appeared to increase the
hazards of gonorrhea, trichomoniasis and the combined endpoint of any STI however these
findings did not reach the threshold for significance. Pregnancy did not appear to increase the
risk of HIV infection (Table 4). Neither oral nor injectable HC use was associated with
increased hazards of any of the four STIs. Site location was not found to be an effect modifier
of the relationship between pregnancy and STI risk in adjusted models.
Discussion
In this secondary analysis of data from an RCT conducted in South Africa and Zimbabwe, we
examined the association between pregnancy status and incidence of chlamydia, gonorrhea,
trichomoniasis and HIV. The analysis included 4,549 women 18–50 years of age of whom, 766
(16.8%) had a pregnancy during follow-up. We found that hazard rates of chlamydia, gonor-
rhea and to a less extent trichomoniasis were higher during periods when women were preg-
nant, however pregnancy did not appear to increase the hazards of STI in multivariable
models adjusted for demographic and time-varying self-reported behavioral risk factors and
vaginal practices.
Our data showed high incidence of chlamydia, gonorrhea and trichomoniasis during preg-
nancy and are some of the first reported data on incidence of these infections in pregnant
women. Pregnant women in our study had higher HIV incidence (3.8 per 100py) than that
reported from two studies conducted in Uganda and Zimbabwe (2004–2007) of between 1.6
[18] and 2.3/100py [19] but lower than data from a study conducted across seven African
countries which found incidence of 7.4/100py (2004–2007) [17]. Among non-pregnant
women, incidence rates in Southern Africa have been shown to range from 3.0 to 6.5/100py
[36–38]. Our data are further confirmation that women in sub-Saharan Africa face high HIV
infection risk which continues during pregnancy. It is important to note that our data are
from 2003–2006, before scale-up of antiretroviral therapy (ART). Limited recent data suggest
that overall HIV incidence is declining in some high prevalence settings, likely as a result of
the expansion of ART [39]. While there are no data specific to pregnant women, it is possible
that incidence of HIV among pregnant women may also be declining.
While our analysis showed pregnant women had higher STI incidence rates compared to
non-pregnant women, especially of chlamydia, pregnancy did not increase the risk of
Table 3. (Continued)
Chlamydia Gonorrhea Trichomoniasis
HR 95%CI AHRa 95%CI HR 95%CI AHRa 95%CI HR 95%
CI
AHRa 95%CI
Insertion of paper (any reported) 1.13 0.86–1.50 1.24 0.92–1.69 0.87 0.54–1.41 0.88 0.53–1.50 1.36 1.05–
1.76e
1.27 0.96–1.69




eOther (diaphragm, IUD, condoms, vasectomy)
fHigh risk sex: exchange, anal sex, >2 partners, new partner, new regular partner
gSTI at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2
https://doi.org/10.1371/journal.pone.0197696.t003
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acquiring any of the infections in adjusted models. A previous analysis of these data, restricted
only to women who had a pregnancy found that while sexual activity decreased during preg-
nancy, condom use was also lower among pregnant women [21]. Thus it may be that any
increased risk in the crude analyses was caused by a change in condom use rather than a
change in biological vulnerability. As noted, there are few data with which to compare these
findings as there have been no previous studies examining increased risk of chlamydia,
Table 4. Crude and adjusteda hazard ratios estimating the relationship between pregnancy status and incident STIs (N = 4,549).
HIV Combined STI endpoint
HR 95%CI AHRa 95%CI HR 95%CI AHRa 95%CI
Pregnancy exposure group (ref: not pregnant/no HC)
Pregnant 0.78 046–1.33 0.75 0.43–1.30 1.18 0.93–1.51 1.15 0.89–1.49
Not pregnant/oral HC 0.58 0.42–0.81c 0.82 0.52–1.31 0.66 0.66–0.78d 0.84 0.67–1.06
Not pregnant/injectable HC 1.07 0.8–1.5 0.81 0.56–1.18 1.13 0.97–1.32 1.07 0.88–1.29
Study location (ref: Harare, Zimbabwe)
Johannesburg, South Africa 2.66 2.01–3.53b 1.91 1.31–2.77c 2.13 1.5–2.47d 1.80 1.49–2.17d
Durban, South Africa 1.30 0.88–1.91 0.89 0.56–1.44 1.80 1.52–2.13d 1.46 1.12–1.82c
Age (ref:35)
18–24 years 2.09 1.44–3.02b 2.51 1.67–3.78d 1.84 1.55–2.19d 2.27 1.87–2.76d
25–34 years 1.34 0.91–1.97 1.65 1.01–2.49b 1.06 0.89–1.27 1.27 1.05–1.56b
Completed high school 1.18 0.91–1.53 1.18 0.90–1.56 1.06 0.94–1.21 1.00 0.87–1.14
Diaphragm arm (ref: control) 1.00 0.80–1.29 0.99 0.76–1.31 1.00 0.88–1.14 1.01 0.88–1.16
Contraceptive use, enrollment (ref: none)
Oral contraceptives 0.85 0.50–1.43 1.35 0.72–2.54 0.64 0.52–0.80c 1.05 0.79–1.39
Injectable contraceptives 1.79 1.07–2.97b 1.83 1.05–3.18b 1.00 0.81–1.26 0.91 0.70–1.17
Other e 1.43 0.85–2.39 1.49 0.89–2.49 0.91 0.73–1.14 0.92 0.73–1.15
High risk sex at enrollment f 1.09 0.82–1.46 1.01 0.81–1.48 1.08 0.93–1.25 0.99 0.85–1.16
Partner circumcised at enrollment 0.94 0.68–1.29 1.00 0.71–1.40 1.43 0.98–1.33 1.08 0.92–1.27
Partner high risk at enrollment 1.61 1.21–2.13c 1.29 0.96–1.74 1.36 1.19–1.56d 1.16 1.00–1.33b
STI at enrollment g 2.00 1.49–2.69d 2.09 1.54–2.85d 1.65 1.43–1.89d 1.74 1.50–2.01d
Vaginal sex since last visit (ref: none) 1.06 0.59–1.89 1.00 0.51–1.92 0.87 0.67–1.14 0.93 0.68–1.27
3 Vaginal sex acts per week (ref:0–2) 0.77 0.59–1.02 0.86 0.64–1.16 0.82 0.71–0.94c 0.96 0.82–1.12
No condom use at last sex 1.00 0.74–1.34 0.94 0.66–1.34 0.99 0.85–1.15 0.92 0.77–1.10
Unprotected sex since last visit 1.26 0.97–1.64 1.22 0.89–1.66 1.25 1.09–1.42c 1.19 1.02–1.39b
Sex in exchange for drugs or money 1.23 0.61–2.49 0.90 0.43–1.89 1.58 1.17–2.16c 1.31 0.94–1.81
2 or more sexual partners 2.29 1.58–3.33d 1.45 0.93–2.25 2.29 1.90–2.76d 1.48 1.19–1.85b
New sexual partner 1.94 1.40–2.68d 1.25 0.87–1.80 1.71 1.45–2.02d 1.17 0.97–1.40
Suspects/knows partner concurrency 1.96 1.51–2.55d 1.42 1.07–1.88b 1.62 1.41–1.85d 1.26 1.09–1.46c
Vaginal washing (any reported) 1.06 0.78–1.42 0.94 0.68–1.30 0.99 0.86–1.15 0.98 0.83–1.15
Vaginal wiping (any reported) 1.37 1.06–1.78b 1.41 1.05–1.89b 1.02 0.90–1.17 1.00 0.86–1.16
Insertion of paper products (any reported) 1.27 0.90–1.81 1.12 0.77–1.64 1.15 0.97–1.38 1.13 0.93–1.37




eOther (diaphragm, IUD, condoms, vasectomy)
fHigh risk sex: exchange, anal sex, >2 partners, new partner, new regular partner
gSTI at enrollment: chlamydia, gonorrhea, trichomoniasis, HSV-2
https://doi.org/10.1371/journal.pone.0197696.t004
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gonorrhea and trichomoniasis during pregnancy. Our findings showing that pregnancy did
not appear to increase HIV incidence is in keeping with three previous analyses which also
found no effect of pregnancy [17, 18, 40]. One study, conducted in Uganda, did find increased
risk [19], however this finding has not been replicated.
This analysis has a number of strengths, as well as some limitations. As noted, there are
very few data on STI incidence during pregnancy and only a small number of longitudinal
studies have examined pregnancy as a risk factor for STI acquisition. Our analysis provides
some of the first data on incidence of chlamydia, gonorrhea and trichomoniasis during preg-
nancy and provides new information regarding pregnancy as an STI risk factor. Another
strength of our analysis was the methodological approach using a time-varying exposure and
risk factors, including intravaginal practices which have not been included in previous analyses
examining pregnancy as a risk factor for HIV acquisition.
A limitation of this analysis was reliance on self-report of sexual risk behaviors, including
condom use which has been shown to be overestimated in biological validation studies [41]. It
is also possible that there was misclassification of HC-use at non-pregnant visits which was
also self-reported and may have had an impact on our results. Some data have shown that
women using injectable progesterone-only hormonal contraceptives are at increased risk for
STIs, including chlamydia, gonorrhea and HIV [32], however our findings do not support
this. If injectable-HC use is associated with STI incidence and women underreported HC-use,
this would have attenuated the effect of pregnancy on STI risk. Our analysis did not distinguish
progesterone only hormonal contraceptives from combined injectable hormonal contracep-
tives. A previous analysis of these same data found a small increased risk of HIV among
women using any injectable hormonal contraceptive which was non-significant and the results
also did not support previous findings of greater risk from progesterone-only injectable hor-
monal contraceptives [42]. Another limitation is that we did not have data on STI status or
risk behaviors collected directly from male partners, all data were based on women’s knowl-
edge of male partner behaviors which may have been inaccurate or incomplete. Testing for
bacterial STI was conducted using DNA PCR on urine samples which has been shown to have
lower sensitivity compared to vaginal swabs for detecting infections, as well as lower specificity
for detecting trichomonas [34, 35]. The PCR testing used in the study may have contributed to
an underestimate of the prevalence of chlamydia and gonorrhea and an over estimate of trich-
omonas measured at enrollment and in detecting incidence during follow-up. It is important
to note that while our measures of prevalence and incidence could have been affected by the
lower sensitivity and specificity of urine PCR testing, the measurement error introduced
would have been non-differential across pregnancy status and would bias our results toward
the null for the main objective of comparing incidence between pregnant and non-pregnant
women. A related additional limitation is that in 2004 Zimbabwe approved intermittent
malaria preventive treatment for pregnant women pregnancy (IPTp) using sulfadoxine–pyri-
methamine (SP) [43]. Sulfanomides, from which sulfadoxine is derived, have been used histor-
ically for the treatment of bacterial and parasitic STIs that include chlamydia, gonorrhea, and
trichomonas [44]. It is therefore possible that the observed incidence of STI among women in
Zimbabwe in the MIRA trial who became pregnant after 2004 and received SP may have been
lower than would be found in an untreated population and this could have led to an underesti-
mate of the relationship between pregnancy and STI incidence. Finally, our statistical analysis
included a multilevel exposure variable (pregnancy and HC use status) which led to multiple
comparisons which could have somewhat increased the likelihood of a type 1 error in finding
statistical significance.
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This analysis provides important information about women’s risk of acquiring sexually
transmitted infections, including HIV. Overall we did not find that pregnancy increased the
risk for acquiring chlamydia, gonorrhea, trichomoniasis or HIV.
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